Clinical Trial Update: Reducing Involuntary Movements in Participants With Tardive Dyskinesia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on reducing involuntary movements in tardive dyskinesia; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tardive Dyskinesia

Snippet

Sponsor: Auspex Pharmaceuticals, Inc. | Conditions: Tardive Dyskinesia | Phase 3 | Status: COMPLETED | Results posted: 2021-03-01